Johnson & Johnson
Medical Device R&D and Manufacturer
2025Year12Month4Johnson & Johnson's medical technology sector (J&J MedTech) officially announced that it will2026Year1Month1Implementing a major organizational restructuring globally starting from [date].——From the existing region-led operating model, fully transition to a business unit-driven approach (Business Unit, BU) as the core of the end-to-end operational system.
This move is seen as Johnson & Johnson Medical's continuation2024At the beginning of the year, the decentralization reform was launched.“The Key Second Step”, aiming to enhance decision-making efficiency, strengthen professional focus, and accelerate global commercial responsiveness.
Why Transform? Reduce Bureaucracy, Improve Efficiency, Strengthen Expertise
According to an internal memo obtained by industry media, the core goal of this organizational restructuring by Johnson & Johnson Medical Technology is to create a“More concise, faster, and more competitive”The organization. Senior management noted in the memo:
“A more decentralized, business unit-led operating model will reduce bureaucratic levels, strengthen accountability and ownership, and help us move faster. This will ultimately enable us to better meet the needs of our customers and patients.”
As early as2024At the beginning of the year, Johnson & Johnson had approximately35,000NameMedTechEmployees are assigned to various business units, initially achieving“Clearer division of responsibilities, more streamlined collaboration processes, and faster decision-making speed”. And2026The comprehensive transformation over the years has been a deepening and institutionalization of this foundation.
Orthopedics Spin-off as Catalyst, Driving Comprehensive Restructuring
Another important driver of this organizational change is Johnson & Johnson's announcement last month of plans to divest one of its core assets.——DePuy SynthesOrthopedics Business. This business accounts for nearly30%The company stated that the spin-off will help two entities operate independently in the future.“Enhance Strategic and Operational Focus to Maximize Shareholder Value”。
Notably, at the same time as the spin-off was announced, the president of Johnson & Johnson Medical Technology's Orthopedics Division also announced his resignation.
The impending independence of the orthopedics business prompts Johnson & Johnson to reassess its remaining three core segments.——Cardiovascular, Surgery, and Ophthalmology——The collaborative mechanism and management structure. The company believes that in the current rapidly evolving medical technology environment,“Must possess deeper professional capabilities and tighter, more agileBUInternal collaboration is essential to succeed in global competition.”。
New Architecture Explained: Who Manages What? What Remains Unchanged?
Self2026Year1Month1Starting from the day, each business unit will take full responsibility for the performance worldwide, covering the complete value chain from product development and market strategy to commercial execution. All commercial leadership will report directly to their respective...BUReport.
The specific arrangements are as follows:
Surgery (Surgery）: by the Chairman of the Company GroupHani AbouhalkaLeader, establish an independent regional management structure;
Electrophysiology and Neurovascular (EP&Neurovascular）: ByMichael BodnerServe as the group chairman and establish a dedicated regional team;
Global Supply Chain: The original supply chain teams in each region will be unified underMedTechVice President of Supply Chain Luis RomanManagement;
Enterprise Functions (such asHR、IT, Legal Affairs, etc.): The structure will be gradually adjusted to better supportBUThe leading new model.
Notably, customer-facing frontline positions have been...BUThe U.S. commercial structure divided by organizations, as well as business units that have adopted this model such as vision care, cardiac rehabilitation, and circulation reconstruction, will not be involved in this adjustment; the operation model in the Chinese market will also remain unchanged.
In addition, Johnson & Johnson will gradually eliminate cross-regionalMedTechJointly lead the team and make adjustments to some executive responsibilities:
Gustavo Gala(Original Latin AmericaMedTechVice President) transferred to oversee the implementation of the new operational model;
Vishnu Kalra(Original Asia-PacificMedTech(Group Chairman) AppointedDePuy SynthesInternational President, reporting directly to the head of the orthopedics business. Namal Nawana Report: From2026Since the year, all overseas (OUS) The person in charge of the orthopedic market and cluster in the region reports toKalraReport;
Gavin Wood(OriginalEMEA MedTechGroup Chairman) will be in2026Continue to support the transition work before the middle of the year.
In the context of increasingly fierce global medical technology competition, Johnson & Johnson Medical Technology has chosen to take the initiative.“Demolition of Walls”, Empower the Frontline, ThroughBUThe leading model打通从创新到市场的全链条。这场始于2024, formed in2026The organizational revolution is not only a reshaping of internal efficiency but also a strategic bet on future growth models. With the spin-off of the orthopedics business and the implementation of the new structure, Johnson & Johnson Medical Technology may usher in a more agile and focused new era.
Reference:MassDevice
